Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Rebecq – page 47

1 850 clinical trials in Rebecq, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Rebecq at a glance
1 850
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 850 trials in Rebecq

Open in trial search

Study on Pelacarsen for Slowing Calcific Aortic Valve Stenosis in Patients

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Study on the Safety and Effects of Divarasib with Pembrolizumab and a Drug Combination for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:F. Hoffmann-La Roche AG

Skin papilloma

Recruiting

Study on the Effectiveness of Interferon Alfa, Interleukin-1, and Interleukin-2 in Treating Non-Genital Warts in Patients

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Interferon Alfa
  • Sponsor:Labo'Life Belgium

Study on the Effectiveness of 2LEBV and 2LXFS for Reducing Fatigue in Patients with Epstein-Barr Virus Infection

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Interferon Alfa
  • Sponsor:Labo'Life Belgium

Study on Darolutamide and Radiation Therapy for Patients with Castration-Resistant Prostate Cancer and Oligometastases

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Unicancer

Long-term Safety Study of Exagamglogene Autotemcel for Patients with Sickle Cell Disease or Transfusion-Dependent Thalassemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Exagamglogene Autotemcel
  • Sponsor:Vertex Pharmaceuticals Inc.

Chondrosarcoma

Recruiting

Study of ivosidenib in adults with advanced or metastatic chondrosarcoma with IDH1 mutation who are untreated or have had one prior treatment

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Study to Determine the Best Dose of Zongertinib with Trastuzumab Deruxtecan or Trastuzumab Emtansine for Patients with Advanced HER2+ Metastatic Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Boehringer Ingelheim International GmbH

Comparison of belantamab mafodotin, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Glaxosmithkline Research & Development Limited

Myelofibrosis+1

Recruiting

Study on the Effectiveness and Safety of Selinexor for Patients with Myelofibrosis and Moderate Thrombocytopenia Who Have Not Used JAK Inhibitors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Karyopharm Therapeutics Inc.

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Erdafitinib and Mitomycin for Patients with Intermediate-risk Non-muscle Invasive Bladder Cancer with FGFR Gene Alterations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Erdafitinib
  • Sponsor:Janssen Cilag International

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Rebecq

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) de-prescribing strategies for patients with chronic usage patterns. This research aims to optimize medication management for individuals with functional dyspepsia and reflux-related conditions.

  • PPI Usage Optimization
  • Digestive Health Management
  • Medication De-prescribing Strategies

The research evaluates different approaches including on-demand usage and alternative treatments, aimed at improving patient care in primary healthcare settings.

02 Primary Care Medicine

Studies examining long-term medication management practices in primary care, with a focus on gastrointestinal disorders and symptom control. This research explores alternative treatment approaches for common digestive complaints.

  • Treatment Optimization
  • Alternative Therapy Evaluation
  • Patient-Centered Care

The research compares various therapeutic strategies to identify the most effective approach for managing chronic digestive conditions in primary care settings.

03 Clinical Therapeutics

Investigation into medication discontinuation strategies, focusing on long-term acid suppression therapy. This research evaluates the effectiveness of different approaches to reducing medication dependence while maintaining symptom control.

  • Therapeutic Alternative Assessment
  • Symptom Management
  • Treatment Efficacy Comparison

The study compares conventional dose reduction methods with newer therapeutic approaches to optimize patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.